PLX 9486

Drug Profile

PLX 9486

Alternative Names: PLX9486

Latest Information Update: 23 Mar 2016

Price : $50

At a glance

  • Originator Plexxikon
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastrointestinal stromal tumours; Solid tumours

Most Recent Events

  • 11 Mar 2016 Plexxikon re-initiates phase Ib trial in Solid tumours and Gastrointestinal stromal tumours in USA (NCT02401815)
  • 17 Jul 2015 Plexxikon suspends phase Ib trial in Solid tumours and Gastrointestinal stromal tumours in USA (NCT02401815)
  • 01 Mar 2015 Phase-I clinical trials in Gastrointestinal stromal tumours (Combination therapy, Inoperable/Unresectable, Locally recurrent, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02401815)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top